Temazepam

Introduction Overview

Generic Name

temazepam

Brand Name

Restoril

Dosage Form

Oral capsule

Drug Class

Benzodiazepines

Pharmacokinetics

Absorption:
Temazepam is rapidly absorbed following oral administration, with peak plasma concentrations typically achieved within 1 to 2 hours. The bioavailability of temazepam is nearly complete, facilitated by its lipophilic nature, which allows efficient penetration through the gastrointestinal tract membranes. Absorption can be influenced by concomitant food intake, which may slightly delay the time to peak concentration but does not significantly affect the extent of absorption. Clinical pharmacokinetic studies indicate that temazepam's onset of action is rapid, correlating well with its absorption profile, making it effective for initiating sleep.

Distribution:
Once absorbed, temazepam is widely distributed throughout body tissues, particularly the central nervous system due to its high lipid solubility. It crosses the blood-brain barrier rapidly, facilitating its sedative effects. Temazepam is approximately 96-98% bound to plasma proteins, predominantly albumin, which influences its volume of distribution and free active drug concentration. Its distribution characteristics contribute to efficacy but also necessitate caution in patients with hypoalbuminemia or altered protein binding, as may be seen in hepatic disease.

Metabolism:
Temazepam undergoes extensive hepatic metabolism primarily via conjugation to inactive glucuronide metabolites. It does not significantly undergo cytochrome P450 oxidative metabolism, thus showing minimal interactions mediated by CYP enzymes. The metabolites are pharmacologically inactive, contrasting with some other benzodiazepines that have active metabolites, leading to a relatively predictable pharmacodynamic profile. Liver function can affect metabolism; in patients with hepatic impairment, clearance may be reduced, necessitating careful dosing.

Elimination:
Elimination of temazepam and its metabolites is primarily renal, with metabolites excreted in the urine. The elimination half-life ranges from 8 to 20 hours, with an average of approximately 11.5 hours in healthy adults. This relatively intermediate half-life allows for effective hypnotic activity without excessive next-day sedation when used appropriately. In elderly patients or those with compromised renal function, elimination may be prolonged, increasing the risk of accumulation and enhanced sedation or adverse effects. Clinical monitoring is advised in these populations.

Dosage Forms

Available Dosage Forms:
Restoril is available in oral capsule formulations. The common marketed strengths include 7.5 mg, 15 mg, and 30 mg capsules. These capsules are intended for oral administration and designed for rapid disintegration and absorption.

Dosages for Adults and Adolescents:
The approved indication for Restoril is the short-term treatment of insomnia in adults. The usual adult dose ranges from 7.5 mg to 30 mg taken orally once daily at bedtime. For transient insomnia or for initiating therapy, a 7.5 mg dosage may be sufficient to reduce sleep latency. Elderly or debilitated patients should start at the lower end of dosing (7.5 mg) with titration based on clinical response and tolerance. Use in individuals under 18 years is not approved.

Specific Patient Populations:
In elderly or debilitated patients, therapy initiation at 7.5 mg is recommended with cautious dose escalation due to altered pharmacokinetics and increased sensitivity. Patients with hepatic or renal impairment require special attention because of reduced metabolism and excretion, increasing the risk of prolonged sedation and adverse effects. The short-term use guideline (generally 7 to 10 days) is particularly important to minimize dependence and withdrawal risk. Pregnancy is a contraindication due to teratogenicity and risk of neonatal withdrawal symptoms. Breastfeeding mothers should consult with healthcare providers, as temazepam can be excreted in breast milk.

Mechanism Of Action

Temazepam, the active ingredient in Restoril, is a benzodiazepine that exerts its pharmacological effects by acting as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA_A) receptor complex in the central nervous system. GABA is the primary inhibitory neurotransmitter in the brain, and by enhancing its effects, temazepam increases neuronal chloride influx, leading to hyperpolarization and a subsequent decrease in neuronal excitability.

At the molecular level, temazepam binds to a specific benzodiazepine recognition site on the GABA_A receptor, distinct from the GABA binding site itself. This binding enhances the affinity of GABA for its receptor, thereby increasing the frequency of chloride channel opening events. This amplified inhibitory neurotransmission results in sedative, anxiolytic, muscle relaxant, and anticonvulsant properties, with the hypnotic effect being the therapeutic focus in Restoril usage.

Clinically, temazepam’s modulation of GABAergic neurotransmission leads to slowing of CNS activity, producing sedation and facilitating the onset and maintenance of sleep in patients with insomnia. Temazepam's intermediate half-life allows for effective sleep induction without excessive next-day sedation when dosed appropriately. Compared to other benzodiazepines, temazepam lacks active metabolites, which limits prolonged sedation and accumulation risks.

Research studies validate temazepam's efficacy and safety profile in the short-term management of insomnia, demonstrating improvements in sleep latency, total sleep time, and quality of sleep. However, chronic use is discouraged due to risks of tolerance, dependence, and withdrawal. Temazepam's mechanism also accounts for some adverse effects such as cognitive impairment and anterograde amnesia, due to widespread GABA receptor activity in brain regions related to memory and cognition.

Pharmacological Actions

Acts as a positive allosteric modulator of GABA_A receptors enhancing inhibitory neurotransmission
Produces sedative and hypnotic effects facilitating sleep onset and maintenance
Exerts anxiolytic effects reducing anxiety associated with insomnia
Has muscle relaxant properties contributing to overall CNS depressant effects
Displays anticonvulsant activity at higher doses though primarily used as a hypnotic
Induces CNS depression leading to drowsiness and sedation
Possesses minimal active metabolites, resulting in predictable pharmacodynamic profile
Enhances chloride ion influx into neurons causing hyperpolarization and reduced excitability
Rapidly crosses blood-brain barrier due to lipophilicity leading to quick onset of action
Modulates central nervous system neurotransmission resulting in calming effects
Causes dose-dependent suppression of REM sleep and alterations in sleep architecture
Can cause anterograde amnesia impacting memory formation during use
May induce respiratory depression when combined with other CNS depressants

Therapeutic Or Clinical Uses

Short-term management of insomnia characterized by difficulty falling asleep
Treatment of transient insomnia episodes associated with situational stress
Facilitation of sleep in patients requiring sedation for medical procedures
Adjunct therapy in anxiety-related sleep disturbances when prescribed appropriately
Management of sleep disorders requiring rapid sleep induction
Temazepam may be used in elderly patients with insomnia with caution and dose adjustment
Short-duration therapy (7 to 10 days) to avoid tolerance and dependence
Off-label use for certain sleep disturbances under careful medical supervision
Occasional use in patients awaiting longer-term behavioral or pharmacologic interventions
Alternative hypnotic for patients intolerant to non-benzodiazepine agents
Supportive treatment in psychiatric conditions where sleep disruption is prominent
Reduction of sleep latency in insomnia improves overall sleep quality and daytime function
Used when non-pharmacological measures for insomnia have failed or are insufficient

Side Or Adverse Effects

Drowsiness and excessive sedation, particularly upon awakening
Dizziness and impaired coordination increasing risk of falls, especially in elderly
Headache and nausea reported in some patients
Confusion, agitation, hallucinations, or depressed mood may occur
Potential for anterograde amnesia and memory impairment
Paradoxical reactions such as increased anxiety or excitability in rare cases
Respiratory depression, especially when combined with opioids or alcohol
Severe allergic reactions including hives, swelling of face, lips, tongue, or throat
Dependence and withdrawal symptoms, including seizures and psychosis upon abrupt cessation
Sleep-related complex behaviors such as sleepwalking, sleep driving, or eating with amnesia
Tolerance development with prolonged use reducing therapeutic effect
Residual next-day sedation affecting alertness and psychomotor performance
Gastrointestinal upset including nausea and vomiting
Mood changes including suicidal ideation or behavior during therapy
Rare but serious neuropsychiatric reactions, necessitating discontinuation

Precautions

Use with caution in patients with respiratory disorders due to risk of respiratory depression
Avoid use in pregnant or breastfeeding women due to fetal harm and neonatal withdrawal risk
Cautious administration in elderly or debilitated patients due to increased sensitivity
Monitor for signs of misuse, abuse, and dependence; use lowest effective dose for shortest duration
Avoid concurrent use with CNS depressants such as alcohol or opioids to prevent additive sedation
Patients with history of depression or suicidal ideation require close monitoring
Avoid abrupt discontinuation to prevent severe withdrawal symptoms
Be cautious in patients with hepatic or renal impairment due to altered metabolism and elimination
Advise patients against performing hazardous activities until alertness is confirmed
Patients should be informed about potential for amnesia and complex sleep behaviors
Storage in secure place to prevent misuse or accidental ingestion
Evaluate risks versus benefits in patients with history of substance abuse
Dose adjustments may be necessary in sensitive populations
Instruct patients to report any unusual mood or behavioral changes promptly
Regular assessment of therapeutic need to prevent long-term dependency

Warnings

Restoril can cause significant respiratory depression or apnea, especially with opioid or alcohol use
Not to be used if less than 7 to 8 hours available for uninterrupted sleep to prevent next-day impairment
Contraindicated during pregnancy due to risk of birth defects and neonatal withdrawal syndrome
Potential for severe allergic reactions requiring immediate medical attention
Risk of addiction, overdose, or death if misused or used without prescription
May cause complex sleep-related behaviors impairing safety (e.g., sleep-driving, sleep-eating)
Use with caution in patients with history of drug or alcohol addiction
Discontinuation should be gradual to avoid life-threatening withdrawal symptoms
Driving or operating machinery is not advisable until full alertness is restored
Do not share medication with others, particularly those with substance abuse history
Be aware of potential interaction with other CNS depressant medications
Use should be limited to short-term duration to minimize dependence risk
Patients experiencing memory loss or unusual behavior should contact healthcare provider
Risk of impaired cognition and psychomotor function in elderly patients
Emergency intervention may be necessary in case of overdose

Contraindication

Hypersensitivity to temazepam or other benzodiazepines
Pregnancy due to teratogenicity and neonatal withdrawal risk
Severe respiratory insufficiency or respiratory depression
Sleep apnea syndrome
Severe hepatic impairment
Myasthenia gravis
Acute narrow-angle glaucoma
Use in pediatric patients under 18 years is not approved
Known history of benzodiazepine hypersensitivity or allergy
Concomitant use with other CNS depressants without medical supervision
Severe psychosis where benzodiazepines are contraindicated
Use in patients with untreated or severe depression with suicidal risk
Concomitant use with potent CNS depressants posing additive risk of respiratory failure
History of substance or alcohol abuse without careful risk assessment
Use in patients unable to remain immobilized or with insufficient time for sleep

Drug Interactions

Enhanced CNS depression when combined with opioids leading to respiratory failure
Additive sedative effects with alcohol causing profound drowsiness or coma
Drug interactions with other benzodiazepines may potentiate adverse effects
Concomitant use with anticonvulsants or barbiturates increases sedation risk
Interaction with CNS depressant muscle relaxants may enhance motor impairment
Some interactions with antipsychotics enhancing sedation and impairing cognition
May potentiate effects of antidepressants, especially tricyclics, increasing sedation
Combination with antifungal agents or HIV protease inhibitors may alter metabolism
Potential interaction with cimetidine affecting temazepam plasma concentrations
Concomitant use with warfarin requires monitoring due to altered effects in some reports
Potential additive respiratory depressant effects with sedative antihistamines
Herbal supplements like kava or valerian may increase sedative load when taken concurrently
Interactions may prolong elimination half-life in elderly or renal-impaired patients
Careful monitoring for intensified side effects when combined with other CNS depressants
Caution when used with agents affecting cytochrome P450 enzymes despite minimal cytochrome metabolism

Preparations Of The Drug

Oral capsules available in 7.5 mg strength
Oral capsules available in 15 mg strength
Oral capsules available in 30 mg strength
Prescription-only status to ensure medical supervision
Packaged for oral administration once daily at bedtime
Formulated for rapid absorption and onset of hypnotic action
Standard formulations contain excipients to promote capsule stability and bioavailability
Generic temazepam preparations available under various trade names
Storage recommendations include controlled room temperature away from moisture and heat
Packaged in blister packs or bottles with child-resistant caps to prevent accidental ingestion
Accompanied by patient medication guides highlighting risks of dependence and misuse
No parenteral or alternative dosage forms commonly available
Supplied primarily for short-term use with clear labeling on duration of therapy
Available in both brand name (Restoril) and generic formulations adhering to quality standards
Healthcare professional labeling includes detailed prescribing information and warnings